10-Q: CNBX Pharmaceuticals Reports Q2 2025 Results, Citing Reduced Operating Expenses Amidst Financial Challenges

Sentiment:

Quarterly Report 14 April 2025 9:05 AM

📋All filings for Cnbx Pharmaceuticals INC

CNBX Pharmaceuticals' Q2 2025 report reveals decreased operating expenses due to funding constraints, alongside ongoing efforts to advance its colorectal cancer drug candidate.

Capital raiseThe company states that it will have to raise funds to pay for its expenses.The company may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party.There can be no assurance that additional capital will be available to the company.The company currently has no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.

Worse than expectedThe company's financial results show a net loss and limited cash reserves, raising concerns about its ability to continue as a going concern.

Summary

CNBX Pharmaceuticals Inc. filed its Form 10-Q for the quarter ended February 28, 2025.
The company is a pre-clinical stage biopharmaceutical company focused on developing innovative medicines for oncology, particularly colorectal cancer.
Their lead drug candidate, RCC-33, is being developed for colon cancer treatment.
For the three months ended February 28, 2025, operating expenses decreased to $64,743 from $240,845 in the same period of 2024.
The net loss for the three months ended February 28, 2025, was $69,788, compared to a net loss of $325,459 for the three months ended February 29, 2024.
For the six months ended February 28, 2025, operating expenses decreased to $101,743 from $490,845 in the same period of 2024.
The net loss for the six months ended February 28, 2025, was $104,140, compared to a net loss of $503,982 for the six months ended February 29, 2024.
As of February 28, 2025, the company had $45,675 in cash and cash equivalents.
The company expects to incur a minimum of $1,000,000 in expenses over the next twelve months.
The company's independent auditors have raised concerns about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial challenges, limited cash reserves, and auditor concerns about its ability to continue as a going concern. While there are some positives, such as reduced operating expenses, the overall outlook is uncertain.

Positives

Operating expenses have been significantly reduced, indicating cost-cutting measures.
The net loss has decreased compared to the previous year, suggesting improved financial performance, although still a loss.
The company is actively pursuing the development of RCC-33 for colorectal cancer, addressing a significant medical need.

Negatives

The company is operating with limited cash reserves, with only $45,675 in cash and cash equivalents as of February 28, 2025.
The company has a history of cumulative losses, raising concerns about its long-term financial viability.
Auditors have expressed concerns about the company's ability to continue as a going concern.
The company's ability to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan.

Risks

The company's limited cash reserves pose a significant risk to its ability to fund ongoing operations and research and development activities.
The company's dependence on raising additional capital exposes it to market conditions and investor sentiment.
The company's reliance on a single drug candidate, RCC-33, concentrates its risk profile.
The company's independent auditors have raised concerns about its ability to continue as a going concern, indicating substantial financial uncertainty.

Future Outlook

The company hopes to start first in human Phase I/II clinical trials in 2023 and expects to incur a minimum of $1,000,000 in expenses during the next twelve months of operations.

Management Comments

The decrease is due to lack of funds.

Industry Context

CNBX Pharmaceuticals operates in the competitive biopharmaceutical industry, specifically targeting oncology with a focus on colorectal cancer. The development of RCC-33 aligns with the industry's ongoing efforts to address unmet medical needs in cancer treatment.

Comparison to Industry Standards

It is difficult to compare CNBX Pharmaceuticals to industry standards due to its pre-clinical stage and limited revenue.
Companies like Celgene (now part of Bristol Myers Squibb) and Roche, which have established oncology portfolios, serve as benchmarks for successful drug development and commercialization.
However, CNBX's financial metrics are significantly lower than these established players, reflecting its early stage of development.

Related Party Transactions

As of February 28, 2025, the Company had One employee, our Director Eyal Barad.
During the six months ending February 28, 2025, the Company paid $ 28,258 in salaries, including socials benefits, to two directors, compared to $ 50,979 for the six months ending February 29, 2024.
As of February 28, 2025, the Company had a balance outstanding payable to two directors: Gabriel Yariv and Eyal Barad in the total of $ 932,771 under Accounts payable and accrued liabilities.
The Company had a balance outstanding on February 28, 2025 and at February 29, 2024 of $ 223,645 payable to Cannabics, Inc.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and dependence on raising additional capital.
Employees may be affected by potential cost-cutting measures or the company's ability to continue operations.
Customers (potential patients) may be impacted by delays in the development of RCC-33 if the company cannot secure sufficient funding.

Next Steps

The company needs to secure additional funding to continue operations and advance the development of RCC-33.
The company hopes to start first in human Phase I/II clinical trials in 2023.
The company needs to manage its expenses carefully to conserve cash.

Key Dates

Date	Description
2004-09-15	CNBX Pharmaceuticals Inc. was incorporated in the State of Nevada.
2010-09-30	The company increased its authorized capital and effected a 20-for-1 reverse split of its issued and outstanding common stock.
2014-04-25	Cannabics, Inc. acquired a majority of the issued and outstanding common stock of the Company.
2014-05-21	The Company changed its name to CNBX Pharmaceuticals Inc.
2014-06-19	FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of CNBX.
2014-08-25	The Company organized G.R.I.N. Ultra Ltd. (GRIN), an Israeli corporation, as a wholly-owned subsidiary.
2020-12-16	The company entered into a Securities Purchase Agreement (SPA) with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $2,750,000.
2020-12-21	The company closed the first tranche and issued a note in the amount of $825,000 (the Initial Note).
2021-02-22	The company closed the second tranche and issued a second note in the amount of $550,000 (the Second Note).
2021-04-23	The company closed the third tranche and issued a third note in the amount of $1,375,000 (the Note).
2022-03-16	The company issued to the investor a demand promissory note (the Demand Note) in the principal amount of $280,000.
2022-05-12	The Company effected a reverse-split of its common stock on a 1:120 basis.
2022-06-15	The Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $154,250.00.
2023-06-12	The Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $65,000.00.
2023-10-13	The Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $24,993.
2024-09-24	The Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $30,000.
2024-12-30	The Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $25,000.
2025-02-03	The Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $55,000.
2025-02-28	End of the quarterly period covered by this report.
2025-04-14	Date of the report filing, with 4,196,841 shares of Common Stock outstanding.

Keywords

pharmaceuticals, oncology, colorectal cancer, RCC-33, clinical trials, financial results, operating expenses, net loss, liquidity, going concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.